The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Remdesivir for the Treatment of Covid-19 — Preliminary Report
Open accessAbstract
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan–Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705. opens in new tab.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy874 · Cited by 413
Pak, K., Uno, H., Kim, D. H., Tian, L., Kane, R. C., Takeuchi, M., Fu, H., Claggett, B., & Wei, L.-J. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2797 · Cited by 269
Surviving Sepsis Guidelines: A Continuous Move Toward Better Care of Patients With Sepsis
Backer, D. D., & Dorman, T. (2017) · JAMA · doi:10.1001/jama.2017.0059 · Cited by 112
Zhao, L., Tian, L., Claggett, B. L., Pfeffer, M. A., Kim, D. H., Solomon, S. D., & Wei, L. J. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0127 · Cited by 40
Research works printed but not linked: 4
- 10.1136/thoraxjnl-2015-207513 · doi:10.1136/thoraxjnl-2015-207513
- 10.1001/jama.1984.03350090023017 · doi:10.1001/jama.1984.03350090023017
- 10.1161/CIRCULATIONAHA.119.040680 · doi:10.1161/circulationaha.119.040680
- Dodd LE, Follmann D, Wang J, et al. Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clin Trials (in press).
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015301 · Cited by 1,362
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
Acute respiratory distress syndrome
Meyer, N. J., Gattinoni, L., & Calfee, C. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00439-6 · Cited by 1,144
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Perrett, H. R., Painter, C. D., Narayanan, A., Majowicz, S. A., Kwong, E. M., McVicar, R. N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.033 · Cited by 1,136
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028700 · Cited by 1,125
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Simonovich, V. A., Burgos Pratx, L. D., Scibona, P., Beruto, M. V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sánchez, M. D. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031304 · Cited by 907
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Fajnzylber, J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., Worrall, D., Giguel, F., Piechocka-Trocha, A., Atyeo, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19057-5 · Cited by 906
The Writing Committee for the REMAP-CAP Investigators, Angus, D. C., Derde, L., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A., van Bentum-Puijk, W., Berry, L., Bhimani, Z., et al. (2020) · JAMA · doi:10.1001/jama.2020.17022 · Cited by 855
COVID-19 and multisystem inflammatory syndrome in children and adolescents
Jiang, L., Tang, K., Levin, M., Irfan, O., Morris, S. K., Wilson, K., Klein, J. D., & Bhutta, Z. A. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30651-4 · Cited by 826
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment
Parasher, A. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138577 · Cited by 776
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Kabinger, F., Stiller, C., Schmitzová, J., Dienemann, C., Kokic, G., Hillen, H. S., Höbartner, C., & Cramer, P. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00651-0 · Cited by 750
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734
COVID-19-neutralizing antibodies predict disease severity and survival
Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser, B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 722
Nadim, M. K., Forni, L. G., Mehta, R. L., Connor, M. J., Liu, K. D., Ostermann, M., Rimmelé, T., Zarbock, A., Bell, S., Bihorac, A., et al. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00356-5 · Cited by 690
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636
The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections
Machhi, J., Herskovitz, J., Senan, A. M., Dutta, D., Nath, B., Oleynikov, M. D., Blomberg, W. R., Meigs, D. D., Hasan, M., Patel, M., et al. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09944-5 · Cited by 617
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Höbartner, C., & Cramer, P. (2021) · Nature Communications · doi:10.1038/s41467-020-20542-0 · Cited by 603
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial
Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., Williams, D. A., Okafor, E. C., Pullen, M. F., Nicol, M. R., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4207 · Cited by 539
Gupta, S., Wang, W., Hayek, S. S., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6252 · Cited by 535
Colunga Biancatelli, R. M. L., Berrill, M., Catravas, J. D., & Marik, P. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01451 · Cited by 512
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19
Majumder, J., & Minko, T. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00532-2 · Cited by 505
Dequin, P.-F., Heming, N., Meziani, F., Plantefève, G., Voiriot, G., Badié, J., François, B., Aubron, C., Ricard, J.-D., Ehrmann, S., et al. (2020) · JAMA · doi:10.1001/jama.2020.16761 · Cited by 499
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Nopp, S., Moik, F., Jilma, B., Pabinger, I., & Ay, C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12439 · Cited by 489
Natural killer cell immunotypes related to COVID-19 disease severity
Maucourant, C., Filipovic, I., Ponzetta, A., Aleman, S., Cornillet, M., Hertwig, L., Strunz, B., Lentini, A., Reinius, B., Brownlie, D., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd6832 · Cited by 484
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US
Auger, K. A., Shah, S. S., Richardson, T., Hartley, D., Hall, M., Warniment, A., Timmons, K., Bosse, D., Ferris, S. A., Brady, P. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.14348 · Cited by 470
Immunopathogenesis and treatment of cytokine storm in COVID-19
Kim, J. S., Lee, J. Y., Yang, J. W., Lee, K. H., Effenberger, M., Szpirt, W., Kronbichler, A., & Shin, J. I. (2021) · Theranostics · doi:10.7150/thno.49713 · Cited by 463
Self, W. H., Semler, M. W., Leither, L. M., Casey, J. D., Angus, D. C., Brower, R. G., Chang, S. Y., Collins, S. P., Eppensteiner, J. C., Filbin, M. R., et al. (2020) · JAMA · doi:10.1001/jama.2020.22240 · Cited by 417
Favipiravir: A new and emerging antiviral option in COVID-19
Agrawal, U., Raju, R., & Udwadia, Z. F. (2020) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2020.08.004 · Cited by 390
Sperotto, F., Friedman, K. G., Son, M. B. F., VanderPluym, C. J., Newburger, J. W., & Dionne, A. (2021) · European Journal of Pediatrics · doi:10.1007/s00431-020-03766-6 · Cited by 385
Hoffmann, M., Hofmann-Winkler, H., Smith, J. C., Krüger, N., Arora, P., Sørensen, L. K., Søgaard, O. S., Hasselstrøm, J. B., Winkler, M., Hempel, T., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103255 · Cited by 385
Song, W.-J., Hui, C. K. M., Hull, J. H., Birring, S. S., McGarvey, L., Mazzone, S. B., & Chung, K. F. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00125-9 · Cited by 372
Piechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 367
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 363
Furtado, R. H. M., Berwanger, O., Fonseca, H. A., Corrêa, T. D., Ferraz, L. R., Lapa, M. G., Zampieri, F. G., Veiga, V. C., Azevedo, L. C. P., Rosa, R. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31862-6 · Cited by 360
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
Lung transplantation for patients with severe COVID-19
Bharat, A., Querrey, M., Markov, N. S., Kim, S., Kurihara, C., Garza-Castillon, R., Manerikar, A., Shilatifard, A., Tomic, R., Politanska, Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe4282 · Cited by 336
SARS-CoV-2 and the pandemic of COVID-19
Adil, M. T., Rahman, R., Whitelaw, D., Jain, V., Al-Taan, O., Rashid, F., Munasinghe, A., & Jambulingam, P. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138386 · Cited by 335
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 327
Emerging treatment strategies for COVID-19 infection
Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I.-G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00671-y · Cited by 326
Systemic and organ-specific immune-related manifestations of COVID-19
Ramos-Casals, M., Brito-Zerón, P., & Mariette, X. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00608-z · Cited by 309
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Forman, R., Shah, S., Jeurissen, P., Jit, M., & Mossialos, E. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.03.013 · Cited by 307
COVID-19 and Solid Organ Transplantation: A Review Article
Azzi, Y., Bartash, R., Scalea, J., Loarte-Campos, P., & Akalin, E. (2021) · Transplantation · doi:10.1097/tp.0000000000003523 · Cited by 301
Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review
Bavishi, C., Bonow, R. O., Trivedi, V., Abbott, J. D., Messerli, F. H., & Bhatt, D. L. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.05.013 · Cited by 298
Zhang, L.-K., Sun, Y., Zeng, H., Wang, Q., Jiang, X., Shang, W.-J., Wu, Y., Li, S., Zhang, Y.-L., Hao, Z.-N., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00235-0 · Cited by 298
Hartley, G. E., Edwards, E. S. J., Aui, P. M., Varese, N., Stojanovic, S., McMahon, J., Peleg, A. Y., Boo, I., Drummer, H. E., Hogarth, P. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf8891 · Cited by 296
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., & Rela, M. (2021) · Inflammopharmacology · doi:10.1007/s10787-020-00773-9 · Cited by 295
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis
Bertolini, A., van de Peppel, I. P., Bodewes, F. A. J. A., Moshage, H., Fantin, A., Farinati, F., Fiorotto, R., Jonker, J. W., Strazzabosco, M., Verkade, H. J., et al. (2020) · Hepatology · doi:10.1002/hep.31480 · Cited by 293
Bramante, C. T., Ingraham, N. E., Murray, T. A., Marmor, S., Hovertsen, S., Gronski, J., McNeil, C., Feng, R., Guzman, G., Abdelwahab, N., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30033-7 · Cited by 291
Rahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 289
Respiratory Virus Infections: Understanding COVID-19
Subbarao, K., & Mahanty, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.004 · Cited by 286
Lamb, Y. N. (2020) · Drugs · doi:10.1007/s40265-020-01378-w · Cited by 284
Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26239-2 · Cited by 280
Trougakos, I. P., Stamatelopoulos, K., Terpos, E., Tsitsilonis, O. E., Aivalioti, E., Paraskevis, D., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 278
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Zha, S., Yamin, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016093117 · Cited by 251
Maghbooli, Z., Sahraian, M. A., Ebrahimi, M., Pazoki, M., Kafan, S., Tabriz, H. M., Hadadi, A., Montazeri, M., Nasiri, M., Shirvani, A., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239799 · Cited by 272
RetractedBlockchain and AI-Based Solutions to Combat Coronavirus (COVID-19)-Like Epidemics: A Survey
Nguyen, D. C., Ding, M., Pathirana, P. N., & Seneviratne, A. (2021) · IEEE Access · doi:10.1109/access.2021.3093633 · Cited by 286
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 262
Humeniuk, R., Mathias, A., Cao, H., Osinusi, A., Shen, G., Chng, E., Ling, J., Vu, A., & German, P. (2020) · Clinical and Translational Science · doi:10.1111/cts.12840 · Cited by 257
Lagier, J.-C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A., Honoré, S., Gaubert, J.-Y., Fournier, P.-E., Tissot-Dupont, H., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101791 · Cited by 254
Dennis, J. M., McGovern, A. P., Vollmer, S. J., & Mateen, B. A. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004747 · Cited by 214
Methodological quality of COVID-19 clinical research
Jung, R. G., Di Santo, P., Clifford, C., Prosperi-Porta, G., Skanes, S., Hung, A., Parlow, S., Visintini, S., Ramirez, F. D., Simard, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21220-5 · Cited by 189
SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?
Woodby, B., Arnold, M. M., & Valacchi, G. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14512 · Cited by 160
Marburg virus disease: a summary for clinicians
Kortepeter, M. G., Dierberg, K., Shenoy, E. S., & Cieslak, T. J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.07.042 · Cited by 160
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
Khoury, D. S., Wheatley, A. K., Ramuta, M. D., Reynaldi, A., Cromer, D., Subbarao, K., O’Connor, D. H., Kent, S. J., & Davenport, M. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00471-1 · Cited by 115
COVID-19 Compared to Other Pandemic Diseases
Pitlik, S. D. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10418 · Cited by 100
Walz, L., Cohen, A. J., Rebaza, A. P., Vanchieri, J., Slade, M. D., Dela Cruz, C. S., & Sharma, L. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-020-05730-z · Cited by 82
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-09-03
- Volume
- 383
- Issue
- 10
- Pages
- 992-994
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3040751560
- Cited by
- 1,396
- References
- 11
- FWCI
- 40.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.